Skip to main content
. Author manuscript; available in PMC: 2022 Feb 3.
Published in final edited form as: Stat Med. 2020 Feb 27;39(11):1641–1657. doi: 10.1002/sim.8503

Table 1. Patient characteristics by prescription of ACEI/ARBs.

Prescribed ACEI/ARB
Baseline Yes (n (%)) No (n (%))
Characteristic (Total = 159 389) (Total = 411 197)
Age (years) 18 to 42 16 616 (10.4%) 94 265 (22.9%)
43 to 53 39 541 (24.8%) 77 224 (18.8%)
54 to 62 36 325 (22.8%) 77 985 (19.0%)
63 to 71 30 667 (19.2%) 75 141 (18.3%)
≥ 72 36 240 (22.7%) 86 582 (21.1%)
Sex Female 62 652 (39.3%) 236 296 (57.5%)
Chronic Kidney Disease Stage ≤ Stage 2 88 826 (55.7%) 146 825 (35.7%)
Stage 3a 10 535 (6.6%) 15 489 (3.8%)
Stage 3b 2728 (1.7%) 3127 (0.8%)
Stage 4 457 (0.3%) 551 (0.1%)
Missing 56 843 (35.7%) 245 205 (59.6%)
Ethnicity White 63 791 (40.0%) 153 747 (37.4%)
South Asian 3072 (1.9%) 4734 (1.2%)
Black 1065 (0.7%) 3905 (0.9%)
Mixed 237 (0.1%) 681 (0.2%)
Other 814 (0.5%) 1623 (0.4%)
Missing 90 410 (56.7%) 246 507 (59.9%)
Comorbidities:
Diabetes Mellitus Yes 44 727 (28.1%) 38 714 (9.4%)
Ischaemic heart disease Yes 42 214 (26.5%) 76 013 (18.5%)
Arrhythmia Yes 17 494 (11.0%) 39 094 (9.5%)
Cardiac failure Yes 18 647 (11.7%) 13 074 (3.2%)
Hypertension Yes 124 340 (78.0%) 240 135 (58.4%)
Other antihypertensives:
Beta-blocker Yes 14 666 (9.2%) 205 156 (49.9%)
Calcium channel blocker Yes 3501 (2.2%) 91 912 (22.4%)
Diuretic Yes 21 950 (13.8%) 129 582 (31.5%)

Abbreviations: ACEI/ARBs, angiotensin-converting enzyme inhibitors or angiotensin receptor blockers. Diuretic: Thiazide diuretics, loop diuretics, or potassium sparing diuretics.